Platelet aggregability and prostacyclin/thromboxane a2 ratio after endoscopic injection sclerotherapy with different sclerosants

H. Yamaga, Makoto Hashizume, H. Wada, S. Kitano, K. Sugimachi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Platelet aggregability and coagulative and fibrinolytic systems were analyzed with regard to positive effects and for side effects of 5% ethanolamine oleate (EO) versus 5% sodium morrhuate (SM) used for endoscopic injection sclerotherapy (EIS). Twelve patients each were treated with each sclerosant. There was a temporary activation of coagulative and fibrinolytic systems within 1 h in both groups. Platelet aggregability was significantly suppressed to 78.6 ± 8.9% of that before EIS in the EO group, but was activated to 110.0 ± 10.5% in the SM group at 1 h after EIS. The ratio of concentrations of prostacyclin (PGI2) to thromboxane A2 (TXA2) increased int he EO group and decreased in the SM group after EIS. The clinical effect in the SM group after the initial session was weaker than that in the EO group with regard to endoscopic findings at the second session. As change in platelet aggregability after EIS is apparently induced by alterations in the ratio of PGI2/TXA2, there would be related effects concerning the sclerosants.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalEuropean Surgical Research
Volume23
Issue number3-4
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Sodium Morrhuate
Sclerosing Solutions
Thromboxane A2
Sclerotherapy
Epoprostenol
Blood Platelets
Injections
ethanolamine oleate

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Platelet aggregability and prostacyclin/thromboxane a2 ratio after endoscopic injection sclerotherapy with different sclerosants. / Yamaga, H.; Hashizume, Makoto; Wada, H.; Kitano, S.; Sugimachi, K.

In: European Surgical Research, Vol. 23, No. 3-4, 01.01.1991, p. 228-234.

Research output: Contribution to journalArticle

Yamaga, H. ; Hashizume, Makoto ; Wada, H. ; Kitano, S. ; Sugimachi, K. / Platelet aggregability and prostacyclin/thromboxane a2 ratio after endoscopic injection sclerotherapy with different sclerosants. In: European Surgical Research. 1991 ; Vol. 23, No. 3-4. pp. 228-234.
@article{91389885b1ab496fb8a348e2b3cf4869,
title = "Platelet aggregability and prostacyclin/thromboxane a2 ratio after endoscopic injection sclerotherapy with different sclerosants",
abstract = "Platelet aggregability and coagulative and fibrinolytic systems were analyzed with regard to positive effects and for side effects of 5{\%} ethanolamine oleate (EO) versus 5{\%} sodium morrhuate (SM) used for endoscopic injection sclerotherapy (EIS). Twelve patients each were treated with each sclerosant. There was a temporary activation of coagulative and fibrinolytic systems within 1 h in both groups. Platelet aggregability was significantly suppressed to 78.6 ± 8.9{\%} of that before EIS in the EO group, but was activated to 110.0 ± 10.5{\%} in the SM group at 1 h after EIS. The ratio of concentrations of prostacyclin (PGI2) to thromboxane A2 (TXA2) increased int he EO group and decreased in the SM group after EIS. The clinical effect in the SM group after the initial session was weaker than that in the EO group with regard to endoscopic findings at the second session. As change in platelet aggregability after EIS is apparently induced by alterations in the ratio of PGI2/TXA2, there would be related effects concerning the sclerosants.",
author = "H. Yamaga and Makoto Hashizume and H. Wada and S. Kitano and K. Sugimachi",
year = "1991",
month = "1",
day = "1",
doi = "10.1159/000129157",
language = "English",
volume = "23",
pages = "228--234",
journal = "European Surgical Research",
issn = "0014-312X",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Platelet aggregability and prostacyclin/thromboxane a2 ratio after endoscopic injection sclerotherapy with different sclerosants

AU - Yamaga, H.

AU - Hashizume, Makoto

AU - Wada, H.

AU - Kitano, S.

AU - Sugimachi, K.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Platelet aggregability and coagulative and fibrinolytic systems were analyzed with regard to positive effects and for side effects of 5% ethanolamine oleate (EO) versus 5% sodium morrhuate (SM) used for endoscopic injection sclerotherapy (EIS). Twelve patients each were treated with each sclerosant. There was a temporary activation of coagulative and fibrinolytic systems within 1 h in both groups. Platelet aggregability was significantly suppressed to 78.6 ± 8.9% of that before EIS in the EO group, but was activated to 110.0 ± 10.5% in the SM group at 1 h after EIS. The ratio of concentrations of prostacyclin (PGI2) to thromboxane A2 (TXA2) increased int he EO group and decreased in the SM group after EIS. The clinical effect in the SM group after the initial session was weaker than that in the EO group with regard to endoscopic findings at the second session. As change in platelet aggregability after EIS is apparently induced by alterations in the ratio of PGI2/TXA2, there would be related effects concerning the sclerosants.

AB - Platelet aggregability and coagulative and fibrinolytic systems were analyzed with regard to positive effects and for side effects of 5% ethanolamine oleate (EO) versus 5% sodium morrhuate (SM) used for endoscopic injection sclerotherapy (EIS). Twelve patients each were treated with each sclerosant. There was a temporary activation of coagulative and fibrinolytic systems within 1 h in both groups. Platelet aggregability was significantly suppressed to 78.6 ± 8.9% of that before EIS in the EO group, but was activated to 110.0 ± 10.5% in the SM group at 1 h after EIS. The ratio of concentrations of prostacyclin (PGI2) to thromboxane A2 (TXA2) increased int he EO group and decreased in the SM group after EIS. The clinical effect in the SM group after the initial session was weaker than that in the EO group with regard to endoscopic findings at the second session. As change in platelet aggregability after EIS is apparently induced by alterations in the ratio of PGI2/TXA2, there would be related effects concerning the sclerosants.

UR - http://www.scopus.com/inward/record.url?scp=0026009399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026009399&partnerID=8YFLogxK

U2 - 10.1159/000129157

DO - 10.1159/000129157

M3 - Article

VL - 23

SP - 228

EP - 234

JO - European Surgical Research

JF - European Surgical Research

SN - 0014-312X

IS - 3-4

ER -